Table 2. One-Sample Mendelian Randomization (MR) Examining the Bidirectional Relationship Between Genetic Predictors of Psoriasis and Coronary Artery Disease (CAD)/Strokea.
| Exposure | Outcome | UK Biobank | |||||
|---|---|---|---|---|---|---|---|
| Full cohort (n = 336 806) | CAD cases (n = 33 466) | CAD controls (n = 303 340) | |||||
| OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | ||
| Psoriasis (109 variants) | CAD | 1.01 (0.99-1.03) | .11 | NA | NA | NA | NA |
| Psoriasis (109 variants) | Stroke | 1.01 (0.98-1.04) | .58 | NA | NA | NA | NA |
| CAD (234 variants) | Psoriasis | 1.04 (0.95-1.14) | .40 | 0.86 (0.67-1.12) | .14 | 1.02 (0.93-1.12) | .66 |
| Stroke (47 variants) | Psoriasis | 1.27 (1.06-1.50)b | .03b | 0.84 (0.53-1.32) | .71 | 1.10 (0.91-1.32) | .66 |
Abbreviations: NA, not applicable; OR, odds ratio.
a
One-sample MR was performed using individual level data on an unrelated White British subset of UK Biobank participants. CAD (33 466 cases) and stroke (10 593 cases) cases were indicated by participant self-report at baseline assessment and/or a primary or secondary diagnosis in linked in-patient hospital episode statistics and/or death registry diagnosis and/or relevant procedure codes and/or primary care diagnosis from linked primary care data. Stratification by CAD status performed to investigate whether commonly prescribed CAD medications mediate observed cardiovascular MR associations.
b
Statistically significant (P < .05) results.